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Objective: Based on a previous randomized study showing significantly superior patency rates for in vitro endothelialized
expanded polytetrafluoroethylene (ePTFE) grafts we investigated whether it was feasible for a nontertiary institution to
offer autologous in vitro endothelialization to all elective infrainguinal bypass patients who had no suitable saphenous
vein available.
Methods: Over a period of 15 years, 310 out of 318 consecutive nonacute patients (age 64.7  8.6) received 341
endothelialized ePTFE grafts (308 femoropopliteal: 153 above knee [AK] and 155 below knee [BK] and 33 femorodis-
tal). Autologous endothelial cells were harvested from short segments (3.9  1.1 cm) of subcutaneous veins (80%
cephalic, 11% basilic, 2% external jugular, and 7% saphenous) and grown to mass cultures within 18.9  4.5 days before
being confluently lined onto fibrin glue-coated ePTFE grafts. The graft diameter was 6 mm (64%) or 7 mm (36%). The
overall procedure-related delay for graft implantation was 27.6  7.8 days. Growth failure prevented 2.5% of patients
from receiving an endothelialized graft. The mean observation period was 9.6 years. Primary patencies were obtained
from Kaplan-Meier survivorship functions. Explants for morphological analysis were obtained from eight patients.
Results: The overall primary patency rate of femoropopliteal grafts was 69% at 5 years (68% [AK] vs 71% [BK]) and 61%
at 10 years (59% [AK] vs 64% [BK]). Primary patency of 7 mm vs 6 mm grafts was 78%/62% at 5 years and 71%/55% at
10 years. The difference between the two groups was statistically significant (log rank test P  .023; Breslow test P 
.017). Stage I vs II/III patients showed 5-year patencies of 67% vs 73% (N.S.) and 10-year patencies of 61%% vs 53%
(N.S.). The primary patency of femorodistal grafts was 52% at 5 years and 36% at 10 years. The limb salvage rate was 94%
(fempop) vs 86% (femdistal) at 5 years and 89% vs 71% at 10 years. All retrieved samples showed the presence of an
endothelium after 38.9  17.8 months.
Conclusion: Autologous in vitro endothelialization was shown to be a feasible routine procedure at a nontertiary hospital.
Explants confirmed the presence of an endothelium years after implantation while the primary patency in the particularly
challenging subgroup of patients without a suitable saphenous vein resembles that of vein grafts. ( J Vasc Surg 2009;49:
352-62.)Thirty years ago vascular surgeons pioneered the field
of tissue engineering by attempting to create endothelial-
ized synthetic bypass grafts. The underlying motivation for
these efforts was the rather disappointing clinical perfor-
mance of small- to medium-sized vascular prostheses. With
the concept of “seeding” autologous endothelial cells into
the meshwork of synthetic grafts vascular surgeons such as
Malcolm Herring1 and Linda Graham2 laid the foundation
for the broad array of today’s tissue engineering efforts
across the disciplines. Initial enthusiasm was great, and
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352many other groups successfully confirmed the concept un-
der experimental conditions. Premature clinical studies,
however, disappointed3,4 and eventually contributed to the
termination ofmost of the programs in the 1980s. In search
for an explanation for the discrepancy between animal
studies and clinical trials, insufficient seeding densities on
themany times longer clinical grafts seemed plausible.With
mass-harvests of endothelial cells from fat tissue in its early
stages5 mass-culture offered an alternative to the minuscule
primary harvest from subcutaneous vein segments.6-8 Yet,
in the absence of precedents, regulatory concerns prevailed
and most of the pioneers of the first hour shied away from
applying tissue culture techniques. Typically, those few
institutions that proceeded with a cell culture-based ap-
proach were European,9,10 partly due to a less stringent
regulatory environment, and partly due to health institu-
tions that were more likely to accept the additional costs
associated with “in vitro” endothelialization than their
American counterparts. In the second half of the 1980s,
sufficient experimental data had been accumulated by a few
groups to justify the commencement of three independent
clinical pilot studies.9-11 In contrast to the “single staged”
seeding trials of previous years, in vitro endothelialization
significantly improved clinical patency rates.9,11-13 Add-
ing weight to these rather small clinical studies was the fact
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confluent endothelium in the midgraft region weeks to
years after implantation.
As the group representing the main proponents of the
treatment, we continually pointed out that it was rather the
principle than the specific approach that we sought to
prove. By choosing the particularly challenging group of
patients who had no saphenous vein available, a long-term
cohort was accumulated and followed up that had no
autologous alternative. By offering the procedure to all
qualifying patients at a nontertiary institution, we intended
to demonstrate that cell culture-based treatments are feasi-
ble at the level of a community hospital.
PATIENTS AND METHODS
Following a controlled, randomized IRB approved trial
between 1989 and 1991, the present cohort of patients was
treated on the basis of informed consent for the “Medical
Prescription of Autologous Cells” as stipulated under Aus-
trian and European Union regulations.
Between June 1993 and December 2007, 570 consec-
utive patients required an infrainguinal bypass graft without
having a suitable saphenous vein available. The lack of a
suitable saphenous vein was a prerequisite for being consid-
ered for in vitro endothelialization. Of these patients, 190
(33%) had an acute indication for surgery andwould therefore
not have tolerated the delay associated with in vitro endothe-
lialization. Another 69 patients (12%) were either operated by
surgeons who chose untreated over endothelialized expanded
polytetrafluoroethylene (ePTFE) grafts (2/3 surgeons in
1993 gradually decreasing to 0/5 surgeons) or defaulted into
this group due to growth failure.One patient refused consent.
Of the remaining patients 310 out of 318 assigned patients
(55%) (203male and 107 female/mean age 64.7 8.6 years)
received in vitro endothelialized ePTFE grafts. Since 33 pa-
tients received endothelialized prostheses bilaterally the over-
all number of in vitro endothelialized ePTFE grafts implanted
in this second enrolment since 1989 was 341. The reason for
a lack of suitable saphenous vein was varicosity in 32%, insuf-
ficient diameter of 3 mm at the preoperative ultrasound
assessment in 42% and the previous harvest of both saphenous
veins in 26%. Of the 341 bypass grafts, 308 were femoropop-
liteal (153 above knee and 155below knee) and 33were distal
reconstructions of which seven received an additional vein-
bridge graft14 using saphenous vein segments (as the overall
length of the saphenous vein would have been too short for
using it as the main graft). Grading of ischemia was done in
accordance with the Rutherford staging system.15,16 In 224
cases, graft implantation was done for grade I ischemia (114
above knee, 101 below knee, 9 distal reconstructions), 39 for
grade II (14 above knee, 16 below knee, 9 distal reconstruc-
tions), and63 for grade III (25 above knee, 38belowknee, 15
distal reconstructions).
Procedural development. Like other tissue engineer-
ing approaches for clinical applications our in vitro endo-
thelialization techniques experienced a gradual improve-
ment over the past 20 years. Especially, the construction of
an easy-to-use and safe rotation device led to an improvedand reliable seeding quality. Similarly, the optimization of
cell culture reagents and culture conditions substantially
shortened the time it took to produce a confluently endo-
thelialized graft. Particularly, the tight monitoring for risk
factors, especially lipids, prior to culturing of endothelial
Fig 1. Immune-fluorescent live-dead stains of control samples
taken immediately after seeding. Overall, 78% of the grafts showed
complete confluence (a), 16% areas of preconfluence (b), and only
6% had minor endothelial-free areas (c).cells led to a significant reduction of growth failures.17
w-den
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of growth impaired cultures through exchange of the se-
rum supplement of the culture medium12 had to be aban-
doned in 1994 because of the unavailability of GMP pro-
duced reagents. Since many patients were already referred
on statins, risk-factor profiles for lipids were downward
biased during the second half of the program. With the
adoption of 7mmprostheses in 1997, a further variable was
introduced.
Endothelial cell harvest. The cell culture laboratory
and the operating room were in close proximity. After
sterile draping of the operating field, short segments of vein
(3.9  1.1 cm) were harvested under local anesthesia
(Cephalic vein [80%]; basilic vein [11%] and external jug-
ular vein [2%]). In 7% of the cases, a segment of the great
saphenous vein was used when the vein was not sufficient
for autografting and/or other veins were not suitable.
Starch-free gloves were principally used to avoid the cyto-
toxic effect of glove powder. After no-touch dissection of
the vein segments and in situ cannulation,6 the veins were
flushed with medium 199 (Gibco, Paisley, UK; 10 ml,
37°C), filled with 0.1% collagenase solution (Worthington
Biochemical Corporation, Freehold, NJ) (37°C) and
kept distended between stop-cocks. The collagenase-filled
vein segments were then transferred to the laboratory
in phosphate-buffered saline solution (PBS) (37°C) in a
sterile thermo-container. After 15 minutes of collagenase
exposure cells were harvested by flushing the vein segment
with M 199 (containing 20% of autologous serum) and
collecting the cell-containing suspension in a sterile tube.
Endothelial cell cultures and graft lining. Primary
cultures were grown in T 12 filter-protected culture flasks
(Falcon, Franklin Lakes, NJ). Successfully grown primary
cultures were passaged at pre-confluence into two 162 cm2
Table. Demographic data and risk factors related to graft
Age Male Fe
AK
Mean/total 65.8 108 4
SD/% 9.1 70.6 2
BK
Mean/total 69.1 96 5
SD/% 8.3 61.9 3
Distal
Mean/total 68.7 22 1
SD/% 8.8 66.7 3
6 mm
Mean/total 68 120 10
SD/% 8.7 58.8 4
7 mm
Mean/total 66.1 97 2
SD/% 8.8 82.2 1
Total
Mean/total 67.5 226 11
SD/% 8.8 66.3 3
AK, Above knee; BK, below knee; HDL, high-density lipoprotein; LDL, loculture flasks (Costar, Cambridge, Mass). A microgridtechnique enabled the daily in situ quantification of avail-
able first-passage endothelial cells. Mass cultures were con-
tinued until the required cell number of approximately
18  106 endothelial cells per graft was reached. The
culture medium consisted of medium 199 supplemented
with 10 ng/mL recombinant bFGF (Boehringer, In-
gelheim, Germany; in phase 2), 50 mg/mL gentamycin
(Gibco, Paisley, UK), 5 mL Fungizone (Sigma) and 20% of
autologous serum. Prior to endothelial cell lining, ex-
panded PTFE grafts of 70 cm length were precoated with
fibrinolytically inhibited fibrin glue (Baxter, Vienna, Aus-
tria) and filled with the endothelial cell suspension
(9.8  3.4  105 EC/mL culture medium). All ePTFE
grafts were ring-reinforced. An even surface distribution of
endothelial cells was achieved through a microprocessor
controlled seeding device (Biegler Electronics, Vienna,
Austria) rotating at 6 rph at 37° for 5 hours, providing a 5%
CO2 atmosphere. After seeding, grafts were left in culture
medium for approximately 9 days to allow the maturation
of the cytoskeleton of endothelial cells and thus increase
their shear stress resistance.
Graft implantation. While the grafts were anasto-
mosed to the arteries, the culture medium was kept-
inside the prostheses by tilting the operating table with-
out ever clamping the endothelialized graft the excess
length was later cut-off. Prior to completion of the distal
anastomosis, the culture medium was flushed out of the
graft. Thin-walled ePTFE (W.L. Gore & Associates, Inc,
Flagstaff, Ariz) was used as graft material. The initial 70
patients received a graft with 6 mm inner diameter. From
then onwards, the graft diameter was chosen to be either
6 mm or 7 mm depending on target-vessel dimensions
and run-off. All patients received anti-aggregatory treat-
ment (oral dipyridamole, 75 mg/d and oral acetyl-sali-
ions and diameters
Grafts
Smoker Nonsmoker Ex-smoker
88 18 47
57.5 7.8 30.4
86 9 60
55.5 5.89 38.7
13 2 18
39.4 6.1 54.5
95 17 111
42.6 7.6 49.8
60 13 45
50.9 11.0 38.1
187 29 125
54.4 8.5 36.7
sity lipoprotein.posit
male
5
9.4
9
8.1
1
3.1
3
6.2
1
7.8
5
3.7cylic-acid 330 mg/d given as combination drug
nt dia
JOURNAL OF VASCULAR SURGERY
Volume 49, Number 2 Deutsch et al 355(Thrombosantin, Boehringer, Ingelheim, Germany) or
anticoagulation treatment (marcumar) when clinically
indicated.
Clinical follow-up. Clinical follow-up was performed
as a prospective cohort evaluation. Patients were seen in the
outpatients department at regular intervals (3 months, 6
months, 1 year, and annually thereafter) and when prompted
by clinical deterioration. Over the entire observation period,
only 11 patients were lost to follow-up, and 48 patients died.
Given the fact that on the basis of a previous randomized
trial the currently reported endothelialization program
was defined as a routine-service for patients without
saphenous veins, first-line patency assessment was based
on significant impairment of claudication distances andwalk-
ing impairment questionnaires18 allowing additional phone-in
screening for patients who could not comply with routine
follow-up appointments. If deteriorations were suspected,
confirmation was based on ankle-brachial index (ABI)
measurement. In case of deterioration of 15% or more or
in patients with media-sclerosis angiography was per-
formed. When Duplex sonography19 became a routine
procedure soon after commencement of the program, it
was adopted as the standard means of patency confirma-
tion. If a significant graft stenosis or occlusion was con-
firmed an angiography was performed. Fifty-eight out of
the initial 80 patients additionally underwent a planned
control angiography after 1 year. Twenty-two patients re-
fused consent.
Morphological investigations. Immediately after the
grafts were taken out of the rotation device and prior to
implantation, control specimens were taken for scanning
electron-(SEM) and epifluorescence microscopy. Samples
for the latter were stained with a vital dye combination
(Live/Dead kit; Molecular Probes, Eugene, Ore). Speci-
Table. Continued
Patients
On Warfarin IDDM NIDDM Glucose
26 33 23 123.32
17.0 21.6 15.0 72.56
45 45 25 113.64
29.0 29.0 16.1 58.68
24 8 3 106.11
72.7 24.2 9.1 53.27
66 47 36 117.85
36.6 24.0 18.4 68.23
29 39 15 116.65
25.9 34.8 13.4 58.89
95 86 51 117.44
27.9 25.2 15.0 65.07
IDDM, Insulin-dependent diabetes melitus; NIDDM, non insulin-dependemen retrieved from eight patients undergoing graft revisionwere initially rinsed in PBS and then transferred into jars
containing 4% formalin (0.1 mol/L in PBS/pH 7.2/4°C).
After transfer to the laboratory, representative samples were
cut off and further processed for (SEM) and histology. In a
first step, SEM samples were transferred into 2% glutaral-
dehyde (0.05 M Cacodylate buffer/pH 7.2/4°C). After
48 hours of fixation, samples were dehydrated in graded
ethanol, critical point dried (CDP 20; Balzers, Liechten-
stein) and investigated with a Jeol JSM 5200 (Tokyo,
Japan). Specimen for histology were further fixed in forma-
lin and then embedded in paraffin. Three m thick sections
were either stained for light microscopy Hemotoxillin-
Eosin ([HE], Azan, Movat) or processed for immune-
fluorescence microscopy (Nikon Eclipse 90i; Nikon, To-
kyo, Japan). Antibodies used were directed against CD31
(Dako Cytomation M0823; monoclonal; Glostrup, Den-
mark), a-SM actin (Fitzgerald Industries, International
Inc., Concord; Mass RDI-ACTINabm-A4; monoclonal),
Ham 56 (Diagnostech; M0632; monoclonal; Glostrup,
Denmark) and CD 68 (Dako Cytomation; M0814; clone
KP1; monoclonal; Glostrup, Denmark), Von Willebrand
Factor-FVIII-(Dako Cytomation; A0082; polyclonal;
Glostrup, Denmark).
Statistics. Statistical analysis of primary patencies was
performed using the Kaplan-Meier survivorship function
(Chicago, Ill). Patencies were compared by the log-rank
test and Gehan’s Wilcoxon test. For group comparisons of
culture data, Student unpaired t test was used. Preoperative
fasting glucose-, cholesterol-, triglyceride (TG)-, lipopro-
tein A-, high-density lipoprotein (HDL)- and low-density
lipoprotein (LDL)-levels were partitioned by follow-up
gap. “Partitioning” was deployed using JMP, a statistical
software package (version 6.0.3, Cary, NC). Recursively,
partitions, in this case patients, based on a hypothetical
mg/%
Cholesterol Triglycerides HDL LDL
218.39 209.79 52.82 124.87
42.80 141.24 17.93 27.45
209.53 196.48 53.46 119.44
55.19 128.00 14.26 36.93
221.75 209.06 51.13 115.37
87.03 148.66 19.46 66.38
221.79 219.79 53.62 120.63
56.82 151.81 15.49 36.36
203.33 173.89 51.83 124.33
44.51 90.10 16.47 35.15
215.66 204.83 52.79 122.31
53.74 136.37 15.92 35.74
betes melitus.relationship between patency and the various parameters
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patient, created a tree of optimal parameter level cut-points
within the cohort of patients being studied. It does this by
an iterative process where all possible cut-points are exam-
ined, settling on a cut-point most likely to produce a
statistically significant difference in patency between the
resulting two groups. Subgroups on either side of cut-
points were correlated with graft patency using the log-rank
test. Comparisons were regarded to be significant with
0.05.
RESULTS
Endothelial cell cultures and graft lining. Overall,
only 2.5% of the 318 patients did not receive an endothe-
lialized graft because of growth failure of endothelial cells.
In the remaining patients primary cultures were ready for
passage on day 9.1  4.0 and seeding of approximately 18
million cells (18.1  8.1  106) onto the grafts was
possible on day 18.9  4.5. After an additional post-
seeding maturation period of 8.7  2.2 days grafts were
implanted 27.6  7.8 days after vein excision. SEM and
vital fluorescence controls of the endothelialization process
showed a completely confluent endothelium in 78% of
freshly seeded grafts (Fig 1, a). Sixteen percent of the
remaining grafts were pre-confluently lined (Fig 1, b) and
only 6% hadminor endothelium-free areas (Fig 1, c). At the
time of implantation, 87% of grafts showed complete con-
fluence, 12% of grafts showed pre-confluence, and only 1%
displayed small nonendothelial-covered areas. Cultures and
grafts were regularly examined regarding microbial con-
tamination. One first-passage culture was found positive for
bacterial infection and replaced by a newly harvested cul-
ture. Microbiology and the postoperative clinical course
confirmed all implanted grafts as noninfected.
Clinical follow-up. The observation time ranged
from 1month to 14.2 years with a mean period of 9.6 years
(Patients at risk are shown in the Table). The ABI had
improved from 0.53 0.18 preoperatively to 0.93 0.31;
0.93  0.30 and 0.87  0.27 at 3 months, 6 months, and
12 months, respectively. It had significantly dropped to
0.39  0.17 prior to intervention. The Kaplan-Meier sur-
vivorship function for femoropopliteal grafts showed an
overall primary patency rate of 69% at 5 years and 61% at 10
years with a limb salvage rate of 94% and 89%. The second-
ary patency was 92% and 85% (Fig 2, a). Differences be-
tween stage I and stage II/III patients were not significant
(Fig 2, b). Above knee grafts had a slightly worse patency
rate than below knee grafts (68% vs 71% and 59% vs 64% at
5 and 10 years, respectively; N.S.) (Fig 3, a). For both
anatomic positions differences between stage I and stage
II/III patients were not significant (Fig 3, b and c). When
7 mm prostheses (n  112) were compared with 6 mm
ones (n  196) there was a significantly better patency in
the 7 mm group (78% vs 62% at 5 years; log rank test P 
.023; Breslow test P  .017) (Fig 4). The distribution of
run off between 6 mm and 7 mm graft was almost identical
with only 6% more patients with a single run-off vessel in
the 6 mm group. Comparisons between patient groupsreceiving 6 mm and 7 mm grafts showed no significant
differences neither with regards to the number of run-off
vessels nor to clinical staging. Since 7 mm grafts were only
implanted from 1996 onwards the longest observation
period for this graft diameter was 11.5 years. The overall
patency for femorodistal reconstructions was 52% and 36%
at 5 and 10 years with a limb salvage rate of 86% and 71%.
Occlusions/critical stenoses. Early occlusions (30
days postoperatively) accounted for 5% of all events, midterm
occlusions (30 days to 3 years postimplantation) for 73% and
long-term occlusions (3 years) for 22%. Of all occlusions,
35% were thrombectomized; 29% were re-operated and re-
ceived a new bypass graft (25% of which were in vitro endo-
thelialized again); 18% had the graft lysed and in the remain-
ing 18% of all occlusions no intervention was indicated.
Angiographic findings. Control angiographies after
1 year largely showed a widely open lumen with no narrow-
ings or surface irregularities. In three out of 58 grafts
moderate wall irregularities were found in the central two-
thirds of the prosthesis. Moderate stenoses were further
seen at the proximal anastomosis in two cases and at the
distal anastomosis in one case. Even distal reconstructions
showed largely pristine year one control angiographies
(Fig 5, a). Minor anastomotic aneurysms were seen in two
patients, one proximal and one distal. None of these
Fig 2. Kaplan-Meier survivorship functions of all patients with
femoropopliteal grafts broken down into primary patency, second-
ary patency, and limb salvage (a), and into stage I and II/III
patients (b), showing patients at risk and standard errors at 1, 3, 5,
and 10 years. The difference between stages was N.S.changes required intervention.
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tances, ABI and Duplex sonographic flow assessment
showed complete or sub-total thrombotic graft occlusion
in 69%. Stenotic changes that required an intervention were
found in 31% of all events, of which 17% were proximal,
33% in the midsegment (Fig 5, a) and 50% in the distal
section of the grafts.
Morphological findings in failed grafts. Specimens
were obtained from eight patients requiring graft revision
38.9 17.8 months after implantation (ranging from 7 to
63 months). Seven out of eight revisions were elective
procedures 5.3  4.3 months after significant in-graft
stenoses had been diagnosed by ultrasound or angiogra-
Fig 3. Patency rates in relation to the distal anatomical position of
the femoropopliteal grafts. Although there was a trend towards
better patency of below knee grafts, it was N.S. (a).When patencies
were broken down into clinical stages for both above knee (b) and
below knee (c) position differences were again N.S.phy. Only one of the stenoses was at the distal anastomosis;the remainder occurred within the mid two-thirds of the
grafts. Histologically, all samples showed eccentric intra-
lumenal tissue formations largely resembling the scar tissue
(pannus) of burnt-out anastomotic intimal hyperplasia
(Fig 6, a and b). This pannus-like tissue was regularly
covered by a confluent CD 31/F VIII-positive endothelial
layer. The remaining circumference of the cross sections
showed three distinctive tissue formations in all explants:
(1) slightly wavy layers of largely acellular material directly
attached to the ePTFE surface and covered by a confluent
endothelium; (2) cell-rich formations of well-aligned -
actin-positive cells (Fig 7, a) often separated form the
confluent endothelium by a distinct, wavy elastin mem-
brane (Fig 7, b); and (3) stretches of densely-packed inflam-
matory cells resting on the ePTFE surface and being di-
rectly covered by a loose sheet of endothelium (Figs 8 and 9).
While foreign body giant cells (FBGC) were regularly present
in these inflammatory areas (Fig 8, a and b; Fig 9), macro-
phages (Fig 8, d) and lymphocytes (Fig 8, c) were alternately
the predominant cell type. Sometimes, dense front-lines of
macrophage-debris infiltrated the surface layer of the
ePTFE (Fig 8, d). Granulocytes were completely absent. In
two of the grafts large thrombi were attached to these
hyper-inflammatory areas (Fig 9). In three of the patients
large pockets of foam cells were found in various locations
between the pannus-like tissue and the ePTFE surface
(Fig 6, c and d).
In general, SEM confirmed the presence of an endo-
thelium on all specimens. Occasionally, some areas were
patchy while others showed overgrowth onto the often
spongy fibrin formations extending from adjacent thrombi.
Risk factor assessment. There was no significant dif-
ference in patency between males and females. Partitioning
of risk factor values by follow-up gap suggested cut-points
for the cohort of patients receiving endothelialized grafts of
203 mg% for glucose; 223 mg/dL for cholesterol; 133
mg/dL for triglycerides; 39 mg/dL for Lipoprotein A; 62
mg/dL for HDLC and 144 mg/dL for LDLC. Freedom
from occlusion between the two sub-groups was only sig-
Fig 4. Comparison of 6 mm with 7 mm grafts showed a signifi-
cant difference in patency. Seven millimeter grafts were only com-
menced 38 months after the 6 mm group and were selected on the
basis of larger popliteal artery diameters.nificant for triglycerides.
bridge anastomosis.
JOURNAL OF VASCULAR SURGERY
February 2009358 Deutsch et alDISCUSSION
Thirty years after its conception an idea could be vin-
dicated that was pioneered by vascular surgeons1,2 and
eventually led to a development later termed “tissue engi-
neering”. Unfortunately, its early failure to translate into a
clinical benefit had also made vascular graft endothelializa-
tion the antithesis of promises in tissue engineering. After a
quarter of a century of successive improvements,6-10 how-
ever, the endothelialization of vascular grafts had devel-
oped from an early prototype of tissue engineering into a
clinically relevant and safe procedure9-13,20 that could be
routinely offered to a sizable cohort of patients in a nonter-
tiary institution.
By providing convincing clinical mid- to long-term
results in femoropopliteal bypass patients who had no
autologous conduit available, we previously showed that a
cell culture-based approach may lead to a significant clinical
benefit.9,12,13,20 By carrying the method over into a rou-
tine procedure at a community hospital, we could counter
the perception that in vitro endothelialization required the
sophisticated infrastructure of a tertiary institution. Simi-
larly, the successful implantation of a confluently endothe-
lialized graft into 97.5% of patients from whom cells were
cultured as well as the absence of graft infection confirmed
the procedure as a reliable routine therapy. By embedding
it into a large cohort of consecutive patients, we could
demonstrate that in spite of the culture-related delay, two-
thirds of infrainguinal bypass patients who have no suitable
saphenous vein available could profit from the method.
Given the fact that our group has been implanting
almost 400 in vitro endothelialized ePTFE grafts over a
period of 20 years,9,12,13,20 procedure- and design-related
changes evolved over time. One of these was the continu-
ation of the program as a routine-service for all patients
without a suitable saphenous vein from 1993 onwards after
the initial randomized study in 50 patients showed signifi-
cantly better patencies with 74% at 7 years in the endothe-
lialized ePTFE group.9,13 Although this step deprived the
current cohort of a nonendothelialized control group, 40
years of clinical data on ePTFE- and saphenous vein grafts
provide well-established baselines.21-25 Particularly in view
of the fact that the patients represented in our cohort were
all lacking a suitable saphenous vein, patency rates resem-
bling or surpassing those of saphenous vein grafts need to
be seen against the particularly low ePTFE results in this
subgroup. The consistent proof of an endothelium in ex-
planted samples obtained between 7 and 63 months after
implantation as well as a trend towards better patencies in
the below knee group further support the view that the
endothelialized grafts behave more like vein grafts than
conventional ePTFE grafts. While this trend had already
been apparent when we reported on the initial 136 patients
of the present cohort,20 an observation period twice as long
and by now a total of 310 patients who received an endo-
thelialized ePTFE graft affirmed the previous patency rates.
Although the first-line determination of long-term patencyFig 5. (a) Stenosed mid-graft segment of an in-vitro endothelial-
ized ePTFE graft. (b) One-year follow-up angiography of an
endothelialized 6mm graft used in a distal reconstruction. Smooth
surface of the endothelialized prosthesis (¡) and no distal anasto-
motic narrowing. An additional bridge-graft (B) reconstruction
had been performed between the posterior tibial and the peroneal
artery with the endothelialized graft inserted near the proximalwas primarily based on clinical assessment, its confirmation
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Since the main purpose of the study was to demonstrate
that in vitro endothelializationmay be provided as a routine
service at the level of a community hospital, open-ended
sophisticated follow-up procedures in asymptomatic pa-
tients exceeding the initial years would have been unfeasi-
ble. Nevertheless, a recent study18 on the relationship
between quantitative and qualitative measures of symptom-
atic peripheral arterial disease found a significant correla-
tion between the two, thus confirming walking impairment
questionnaires as a reliable method of first-line patency
screening.
One other development over time was the introduction
of 7 mm prostheses for larger popliteal target vessels in year
four. Although the significantly better patency rate of 7mm
grafts may well be due to a better run-off, a 5-year patency
of 78% in the endothelialized 7 mm group is still remark-
able particularly in a situation where the 6 and 7mmgroups
neither differed with regards to clinical staging nor to the
number of patent crural run-off arteries. A further inhomo-
genicity over time resulted from the developments associ-
Fig 6. Midgraft segments explanted at the time of re-op
(b) and (d) after implantation of an in vitro endothelialize
significant stenoses but the displayed prestenotic regions
Typically, the foam cells were wedged underneath pann
complete acellularity (A) (c). Masson’s Trichrome Stain
0.5 (a) and (b) and 10 (c) and (d).ated with the human immunodeficiency virus (HIV) pan-demic and the emergence of lipid-lowering drugs in the
1990s. After previous studies established a link between
growth-failure of endothelial cells as well as patency of
endothelialized grafts on the one hand and preoperative
lipid levels on the other, growth-failure of primary endo-
thelial cultures could be dramatically reduced from 27%9 to
5%20 by the timely exchange of the patients own serum
with low-lipid pool-serum. With the emerging need of
polymerase chain reaction-analyses for the exclusion of
HIV infection and the availability of lipid-lowering drugs
serum exchange was abandoned at an early stage and lipid-
control became routine leading to an almost complete
absence of growth failure. Since most patients were admit-
ted when they were already on lipid-lowering drugs, our
observation of a continual correlation of higher preopera-
tive triglyceride levels with lower patencies of the endothe-
lialized grafts needs to be seen in perspective. Nevertheless,
since statins do not lower TGs by more than 10% to 15%
and higher TG are associated with more remnants of
atherogenic small dense LDL and lower HDLC the corre-
lation still holds predictive value. This is particularly impor-
n for graft failure 41 months (a) and (c) and 63 months
FE graft. Both specimens contained other areas of more
packed with large islands of foam cells (F) (c) and (d).
e cell-poor tissue that occasionally showed stretches of
tched” images to represent objective magnifications oferatio
d ePT
were
us-lik
; “stitant in view of the distinct atherogenic lesions found in a
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failed endothelialized grafts.
This leads to the main question of how endothelialized
ePTFE grafts fail. At first glance, thrombosis seems to be
prevalent occurring primarily between day 30 and 3 years
nurturing the suspicion that the endothelium may have
disappeared. Histologic analysis of failed midgraft seg-
ments, however, revealed that highly inflammatory suben-
dothelial areas together with hyperplastic narrowings may
account for these occlusions rather than the absence of an
endothelium. Although one needs to keep in mind that
midgraft specimens were only obtained from eight patients,
they all stem from failed grafts. The most significant finding
was that subendothelial connective tissue cells were present in
abundance in midgraft regions that otherwise hardly ever
Fig 7. Different area of the same specimen as in Fig 6a and c of an
endothelialized graft 41 months after implantation. Relatively
extended areas were typically found in most explants where a
confluent endothelium was resting on a layer of well-aligned
-SMC actin-positive cells (a) (Immunofluorescence -SMC ac-
tin/CD31; Dapi nuclear counter stain/CD 31; 10 objective) A
delicate intima was demarcated from the actin positive cells by a
well-defined elastic membrane. Orcein stain; 10 and 20
objectives.show tissue formations in non-endothelialized ePTFE grafts.The source of the often smooth muscle-like cells could either
be contamination during culture, something which would
have been noticed in the course of 19 days of mass culture,
homing of circulating progenitor cells enabled through the
presence of an endothelium or transdifferentiated endothe-
lial cells. The often eccentrically narrowing formations of a
pannus-like tissue,whose potential precursorsmaybe themild
luminal irregularities visible on 5% of year one angiographies
Fig 8. Areas of confluent endothelium (°) lying in direct proxim-
ity to densely packed inflammatory cells, which were directly
resting on the ePTFE surface without any connective tissue cells.
Explant samples of four different patients 27 months (a), 14
months (b), 29 months (c), and 63 months (d) after implantation.
Foreign body giant cells (*) were regularly present, either directly
attached to the ePTFE (a) or tucked underneath the endothelium
(b). Some areas consisted almost exclusively of lymphocytes (c)
while others were dominated by macrophages (d). Occasionally,
macrophage debris (↔) was densely packed into the surface layer
of the ePTFE (d). Double-immunofluorescence Ham56/CD68
and CD31; Dapi nuclear counter stain; 10 (a), (c), and (d), and
40 (b) objectives.in the present cohort and described by others,11 presented a
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sclerotic lesion and its large accumulations of foam cells in the
depth. Most peculiar, however, were those stretches were a
thin layer of endothelium was directly attached to a densely
packed layer of inflammatory cells wedged between the endo-
thelium and the ePTFE surface. These areas were associated
with sometimes large surface thrombi confirming the obser-
vation of the 1980s that inflammation turns an endothelium
into a procoagulatory entity. The proinflammatory role of
lipids in this process can just be speculated.
In summary, we have shown in a cohort of 341 infrain-
guinal in vitro endothelialized ePTFE grafts that a largely
confluent autologous endothelium can be safely provided
on ePTFE prostheses for 97.5% of elective patients within
less than 4 weeks and without the occurrence of infections.
Since only one-third of the overall 465 patients were unable
to wait for the completion of the procedure due to acute
clinical symptoms, autologous in vitro endothelialization
can be seen as a potential therapy for two-thirds of the
patients in need of an infrainguinal bypass grafts who have
no suitable saphenous vein available. Long-term patencies
resembling vein grafts together with the fact that the pro-
cedure has been uninterruptedly provided as a routine
therapy at a nontertiary hospital for 15 years may help to
overcome the perception that complexity outweighs the
benefit.
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Dr G. Patrick Clagett (Dallas, Tex). Have you used platelet-
imaging studies to document the creation of a nonthrombogenic
surface and, thereby, prove indirectly that there are viable endo-
thelial cells on the prosthetic surface?
Dr Peter Zilla.We have done a preclinical study in primates in
the mid-’80s. What it clearly demonstrated was a nonthrombo-
genic surface. However, in the beginning, you see quite a lot of
inflammatory cells on top of the in vitro-lined endothelium, which
after 4 weeks have completely disappeared.
Dr Rajabrata Sarkar (San Francisco, Calif): Many groups
have tried for years to get endothelium to grow on PTFE [poly-
tetrafluoroethylene] grafts. And now we know that stem cells are
always attracted to sites of vascular inflammation. Andmy question
for you is: Do you think that the cells that you find at explantation
are actually the endothelial cells that you seeded, or have you just,
with the fibrin glue, created a better landing site for these circulat-
ing endothelial-like stem cells?
DrZilla.This is a very good point. I would go one step further
and expand it beyond the endothelial cells. The fact that we found
actin-positive cells in the subendothelial layers and, in some areas,
even tissue that resembles a vascular wall, makes one wonder how
these cells got there. So far, we could not answer whether the
originally transplanted endothelial cells transdifferentiated into
actin-positive cells or whether the graft surfaces were homing sites
for circulating cells.
Dr Sarkar. And my follow-up question is: How do you
confirm that these are actually endothelial cells? Because exposed
smooth muscle cells, when exposed to laminar flow, will line up in
an endothelial cell-like monolayer.
Dr Zilla. I showed a series of immunofluorescence pictures.
We didn’t only use factor VIII but also CD31 and transmission
electron microscopy. The surface cells were all very clearly endo-
thelial cells.
Dr Alexander Clowes (Seattle, Wash). I am intrigued by your
morphology. Have you had the opportunity to do longitudinal
studies using duplex scanning or MR [magnetic resonance] to findDr Zilla. It would have been great had we also done such a
clinical study in a tertiary hospital, but this study was done in a
community hospital with the purpose of demonstrating that the
method can really be done everywhere as a clinical routine service
without academic sophistication. Therefore, the answer is no, we
don’t have this information, but the fact that the 1-year follow-up
hardly showed any surface irregularities indicates that the process is
slow and scarce.
Dr Kai Balzer (Dusseldorf, Germany). Three questions. First
one, the hope to make the layer of endothelium was to inhibit
myointimal hyperplasia. The pictures you showed kind of ques-
tioned that from the few specimens you obtained. The second
question, have you ever tried—because from our experience, en-
dothelial cells that you gain from veins sometimes lose the possi-
bility to proliferate after several cell cycles—have you ever tried
endothelial progenitor cells from the bone marrow? And the third
question would be, have you ever tried labeling your cells that
maybe even after 1 year you could see if those cells that you
implanted were the ones still on the graft.
Dr Zilla. Let me start with the first question. The fact that in
some areas we end up with a double layer where the actin-positive
subendothelial cells show signs of a contractile phenotype indicates
that the cells on the graft surface may attempt to emulate some-
thing physiological. Why other areas have an endothelium lying on
naked blank PTFE after 63 months with inflammatory cells stuffed
in between, I can’t explain.
With regards to labeling: Remember, Manfred Deutsch and I
are veterans in that field, so even the last leg of the academic part of
the study was performed more than 15 years ago, when methods
such as adeno-associated viruses to deliver green fluorescent pro-
tein were not available yet. But I would love to see a follow-up on
that question done by younger colleagues.
Dr Balzer. And progenitor cells?
Dr Zilla. The same applies here: based on the encouragement
of the long-term clinical results, a new round of academic interest
seems justified.
